Why Is German Biotech Affimed Stock Soaring On Monday?
Portfolio Pulse from Vandana Singh
Affimed N.V. (NASDAQ: AFMD) shares surged on Monday following the release of promising clinical data from its AFM24-102 study in non-small cell lung cancer (NSCLC). The data showed significant clinical efficacy and a manageable safety profile for the combination of AFM24 and atezolizumab, leading to an 81.4% increase in AFMD's stock price.
June 03, 2024 | 6:13 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Affimed N.V. (NASDAQ: AFMD) shares surged 81.4% on Monday after the company announced promising clinical data from its AFM24-102 study in NSCLC. The data showed significant clinical efficacy and a manageable safety profile for the combination of AFM24 and atezolizumab.
The significant increase in AFMD's stock price is directly tied to the positive clinical data from the AFM24-102 study. The data showed high efficacy and a manageable safety profile, which are critical factors for investor confidence in biotech stocks.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100